Search
for
Sort by
Research 31–60 of 72
- Drug-Induced Hair Changes
- Cutaneous toxicities of new treatments for melanoma
- The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma
- A Unique Case of Pili Multigemini Complicated by Folliculitis: Unveiling the Intricacies of a Rare Hair-Follicle Disorder
- The JAK/STAT signaling pathway: from bench to clinic
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Dissolving microneedles: Applications and growing therapeutic potential
- Advances and Prospects for Hydrogel-Forming Microneedles in Transdermal Drug Delivery
- Microneedle Arrays Combined with Nanomedicine Approaches for Transdermal Delivery of Therapeutics
- Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views
- Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
- Topical delivery of nanoemulsions for skin cancer treatment
- IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes
- The influence of interferon on healthy and diseased skin
- Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Exploring the relationship between anastasis and mitochondrial ROS-mediated ferroptosis in metastatic chemoresistant cancers: a call for investigation
- Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches
- Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
- Autophagy: Guardian of Skin Barrier
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Cancer-Related Alopecia: From Etiologies to Global Management
- Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
- Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
- Targeting the Warburg Effect in Anaplastic Thyroid Carcinoma: Metabolic Vulnerabilities and Therapeutic Opportunities